Novo secures EU approval for FREHEMGO in haemophilia A

FREHEMGO is a next-generation bispecific antibody that mimics activated factor VIII (FVIIIa), a protein needed for normal blood clotting.

DENMARK—Novo Nordisk has received approval from the European Commission for FREHEMGO® (denecimig) in Denmark and other EU member states to prevent or reduce bleeding episodes in adults and children with haemophilia A, including those with or without inhibitors.

The authorisation, announced in November 2026, follows a positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September 2026.

FREHEMGO is a next-generation bispecific antibody that mimics activated factor VIII (FVIIIa), a protein needed for normal blood clotting.

Administered through a subcutaneous injection, the treatment offers three dosing options: once weekly, every two weeks or once monthly.

Patients can administer it using a single-use pre-filled pen, allowing them to choose a schedule that suits their treatment needs.

Flexible dosing expands treatment options

The approval gives people with haemophilia A and their healthcare teams another prophylactic option, particularly for patients who require alternatives to conventional factor replacement therapy.

Maria Elisa Mancuso, Medical Member of the Board of Directors of the World Federation of Hemophilia and Senior Haematology Consultant at IRCCS Humanitas Research Hospital in Milan, Italy, said treatment advances could reduce the burden of planning daily activities around the risk of bleeding.

She noted that additional treatment options allow patients and clinicians to consider individual needs and how therapy fits into everyday activities, including education, employment, sports and family life.

Clinical trials demonstrate bleeding reduction

The European approval draws on findings from Novo’s FRONTIER clinical trial programme.

In the pivotal FRONTIER2 study, denecimig significantly reduced annualised bleeding rates compared with previous clotting factor prophylaxis and on-demand treatment among people with haemophilia A, both with and without inhibitors.

Results from FRONTIER3, which evaluated children younger than 12 years, were consistent with the efficacy observed in adolescents and adults.

Across the programme, participants recorded low mean annualised bleeding rates, with a substantial proportion experiencing no treated bleeding episodes.

The FRONTIER5 study also assessed patients who switched directly from emicizumab to denecimig.

Researchers reported no new safety signals, while participants showed a preference for the pre-filled pen over previous administration methods.

The treatment also maintained increased thrombin generation within the normal range without producing levels associated with potential thrombotic risk.

Martin Holst Lange, Novo’s Chief Scientific Officer and Executive Vice President of Research and Development, said the approval reflected findings from the FRONTIER programme, which demonstrated bleeding protection across different age groups and inhibitor status.

He acknowledged the contribution of researchers, clinical investigators and patients who participated in the studies, noting that their involvement supported the development of another treatment option for haemophilia A.

Regulatory expansion

FREHEMGO has also received marketing authorisation in Saudi Arabia. Meanwhile, the US Food and Drug Administration (FDA) and other regulatory authorities are reviewing the treatment.

The European approval expands Novo’s presence in the haemophilia treatment market, where longer dosing intervals and simplified administration are increasingly important considerations in treatment development and patient access.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.

Visited 9 times, 9 visit(s) today

Newer Post

Thumbnail for Novo secures EU approval for FREHEMGO in haemophilia A

PAHO urges Americas to intensify measles response as outbreaks threaten elimination

Older Post

Thumbnail for Novo secures EU approval for FREHEMGO in haemophilia A

Isomorphic Labs raises US$5B to advance AI-driven drug discovery

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *